Receive our newsletter – data, insights and analysis delivered to you
March 1, 2012

Ambry exome sequencing test found to diagnose genetic disorders

Ambry Genetics has reported beneficial results from its Clinical Diagnostic Exome testing, used to diagnose individuals with genetic disorders.

By admin-demo

Ambry Genetics has reported beneficial results from its Clinical Diagnostic Exome testing, used to diagnose individuals with genetic disorders.

Exome sequencing testing offers a cost and time effective method to diagnose genetic diseases that are associated with multiple genes for which limited testing and / or no comprehensive panels are available.

Using the company’s clinical diagnostic exome testing, four individuals with rare genetic conditions who could not be previously identified were successfully diagnosed, at the Kennedy Krieger Institute in Baltimore, US, and Ivy League-affiliated university hospital in New York City.

In one of the cases at the Kennedy Krieger Institute, the exome sequencing test revealed that the patient’s condition is a form of autosomal recessive intellectual disability caused by mutations in the ELP2 gene.

Ambry Genetics chief executive officer Charles Dunlop said the company is the first CLIA-certified lab to provide whole exome sequencing and deliver actionable results from an exome test.

"Our clinical diagnostic exome test is now available to clinicians and their patients across the country and is already covered by some national health insurance carriers," Dunlop added.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Ambry Genetics assistant medical director Elizabeth Chao said they look forward to documenting the patient-specific results further, and to conducting additional tests in coming months.

The test will quickly identify the causes of a wide range of genetic disorders that previously have gone undiagnosed by targeting the exons of nearly all genes, unlike the traditional genetic testing that analyses only one or a few specific genes at a time, the company said.

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory, focused on clinical diagnostics and genomic services, particularly in sequencing and array services.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU